Olaparib effective against BRCA2-mutated prostate cancer

The anti-cancer drug olaparib may be effective in treating biochemically recurrent prostate cancer without accompanying hormone therapy for men who have mutations in genes such as BRCA2, according to results of a phase II clinical trial of 51 patients conducted at the Johns Hopkins Kimmel Cancer Center and three other sites.


http://dlvr.it/TCGqDP

Comments

Post a Comment

Popular posts from this blog

GLP-1 Drugs Before Bariatric Surgery Can Help People With Extreme Obesity

Image
A new study looked at the impact of taking GLP-1 drugs before bariatric surgery. Halfpoint/Getty Images * New research finds that using GLP-1 drugs like Ozempic before bariatric surgery can help improve the health of people with extreme obesity. * Extreme obesity is defined as having a body mass index (BMI) of 70 or more. * In 2022, there were nearly 280,000 metabolic and bariatric surgeries in the United States. People with extreme obesity can reduce their risk of complications from bariatric or metabolic surgery by taking GLP-1 drugs before the procedures, according to a study presented over the weekend at the American Society for Metabolic and Bariatric Surgery (ASMBS) 2024 Annual Scientific Meeting. The results of the study haven’t yet been published in a peer-reviewed scientific journal. Extreme obesity, which is defined as having a body mass index (BMI) of 70 or more, presents patients and doctors with complications during and after weight-loss surgery c...
Read more